| Q37053762 | ABC multidrug transporters in schistosomes and other parasitic flatworms |
| Q79658011 | Antibody response in mice infected with Mesocestoides vogae (syn. Mesocestoides corti) tetrathyridia after treatment with praziquantel and liposomised glucan |
| Q38108554 | Antiparasitic treatment of cerebral cysticercosis: lessons and experiences from China |
| Q37674908 | Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms |
| Q28480620 | Antischistosomal activity of trioxaquines: in vivo efficacy and mechanism of action on Schistosoma mansoni |
| Q38077463 | Application of praziquantel in schistosomiasis japonica control strategies in China |
| Q87970977 | Biochemical characterization and role of the proteasome in the oxidative stress response of adult Schistosoma mansoni worms |
| Q36434081 | Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature |
| Q34760480 | Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E |
| Q79239916 | Chemotherapy of schistosomiasis: an update |
| Q44607347 | Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel |
| Q71485459 | Distribution and biophysical properties of fluorescent lipids on the surface of adult Schistosoma mansoni |
| Q33555427 | Drug resistance in human helminths: current situation and lessons from livestock |
| Q53689348 | Effects of Callistemon citrinus aqueous extract on prepatent and patent infections with Schistosoma mansoni in experimentally infected mice. |
| Q45897853 | Efficacy and safety of oral praziquantel against Dicrocoelium dendriticum in llamas |
| Q35111888 | Efficacy of garlic based treatments against monogenean parasites infecting the guppy (Poecilia reticulata (Peters)). |
| Q60690767 | Evidence for ryanodine receptors in Schistosoma mansoni |
| Q88911135 | Genistein: is the multifarious botanical a natural anthelmintic too? |
| Q39140065 | Genital schistosomiasis in women: a clinical 12-month in vivo study following treatment with praziquantel |
| Q43901475 | Heterogeneities in anti-schistosome humoral responses following chemotherapy |
| Q48478663 | How has the genomics era impacted schistosomiasis drug discovery? |
| Q28543846 | Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel |
| Q43698487 | Investigation of praziquantel metabolism in isolated rat hepatocytes |
| Q34782668 | Ion channels and drug transporters as targets for anthelmintics |
| Q33780103 | MIND-BEST: Web server for drugs and target discovery; design, synthesis, and assay of MAO-B inhibitors and theoretical-experimental study of G3PDH protein from Trichomonas gallinae. |
| Q33552868 | Modulation of a Schistosoma mansoni multidrug transporter by the antischistosomal drug praziquantel |
| Q33806779 | NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum |
| Q37177725 | New approaches for understanding mechanisms of drug resistance in schistosomes |
| Q37943763 | New insight into praziquantel against various developmental stages of schistosomes |
| Q38253124 | New uses for old drugs: the tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China. |
| Q35159499 | Pharmacology and potential physiological significance of schistosome multidrug resistance transporters |
| Q73338045 | Praziquantel has no direct effect on (Na(+)+K+)-ATPases and (Ca2(+)-Mg2+)ATPases of Schistosoma mansoni |
| Q28537753 | Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections |
| Q41365181 | Prospects for rational approaches to anthelmintic discovery |
| Q39078061 | Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain |
| Q28480972 | Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis |
| Q48016286 | Schistosoma mansoni Ca2+-ATPase SMA2 restores viability to yeast Ca2+-ATPase-deficient strains and functions in calcineurin-mediated Ca2+ tolerance |
| Q33960332 | Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel |
| Q34705514 | Schistosome ABC multidrug transporters: From pharmacology to physiology |
| Q39143568 | Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel |
| Q80098643 | Schistosome resistance to praziquantel |
| Q34354490 | Schistosomiasis chemotherapy. |
| Q39409750 | Schistosomiasis control in the People's Republic of China |
| Q40791018 | Senna leaf extracts induced Ca(+2) homeostasis in a zoonotic tapeworm Hymenolepis diminuta |
| Q44667713 | Specific sites in the Beta Interaction Domain of a schistosome Ca2+ channel beta subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel |
| Q58070149 | The anti-schistosomal drug praziquantel is an adenosine antagonist |
| Q34278624 | The biochemical basis of anthelmintic action and resistance |
| Q91898993 | The impact of cinnarizine and griseofulvin on juvenile and adult stages of Schistosoma mansoni |
| Q56985255 | Tomocomd-Cardd, a novel approach for computer-aided ? rational? drug design: I. Theoretical and experimental assessment of a promising method for computational screening and in silico design of new anthelmintic compounds |
| Q33914691 | Towards an understanding of the mechanism of action of praziquantel |
| Q36442593 | Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro |
| Q28489110 | Transcriptional responses of in vivo praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKII |
| Q40079529 | Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens |
| Q43300665 | Urinary soluble egg antigen levels in Schistosoma haematobium infection in relation to sex and age of Kenyan schoolchildren following praziquantel treatment |
| Q36424568 | Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action |